UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2010
MYRIAD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-34275 | | 26-3996918 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
305 Chipeta Way
Salt Lake City, UT 84108
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (801) 214-7800
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On April 22, 2010, Myriad Pharmaceuticals, Inc. (“MPI”) held its previously announced Special Meeting of Stockholders, at which a quorum was present. At the Special Meeting, the stockholders of MPI voted to approve an amendment to MPI’s restated certificate of incorporation to change the name of the company from “Myriad Pharmaceuticals, Inc.” to “Myrexis, Inc.” The affirmative vote of holders of a majority of the 24,611,101 shares of MPI common stock outstanding on March 8, 2010, the record date for the Special Meeting, was required for approval of this proposal. The table below shows the number of votes cast for or against as well as the number of abstentions on the proposal. There were no broker non-votes on this proposal.
| | | | |
FOR | | AGAINST | | ABSTAIN |
18,285,718 | | 414,753 | | 82,826 |
There were no other proposals voted on at the Special Meeting.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | MYRIAD PHARMACEUTICALS, INC. |
| |
| Dated: April 23, 2010 | | /S/ ADRIAN N. HOBDEN |
| | Adrian N. Hobden, Ph.D. |
| | President and Chief Executive Officer |
3
